{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonalcoholic+Steatohepatitis+With+Liver+Fibrosis&page=3",
    "query": {
      "condition": "Nonalcoholic Steatohepatitis With Liver Fibrosis",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonalcoholic+Steatohepatitis+With+Liver+Fibrosis&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonalcoholic+Steatohepatitis+With+Liver+Fibrosis&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T08:10:11.795Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01672879",
      "title": "Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Fibrosis Due to NASH"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SIM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 259,
      "start_date": "2012-10-29",
      "completion_date": "2017-01-03",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Coronado, California • San Diego, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01672879"
    },
    {
      "nct_id": "NCT02548351",
      "title": "Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Alcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 2477,
      "start_date": "2015-09-22",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 175,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548351"
    },
    {
      "nct_id": "NCT02686762",
      "title": "Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Steatohepatitis",
        "Fibrosis",
        "Liver Diseases"
      ],
      "interventions": [
        {
          "name": "Emricasan (5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Emricasan (50 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 318,
      "start_date": "2016-01-26",
      "completion_date": "2019-02-28",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Freestone",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02686762"
    },
    {
      "nct_id": "NCT02704403",
      "title": "Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH) With Fibrosis"
      ],
      "interventions": [
        {
          "name": "Elafibranor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genfit",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2157,
      "start_date": "2016-03",
      "completion_date": "2020-10-28",
      "has_results": true,
      "last_update_posted_date": "2022-03-23",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 153,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02704403"
    },
    {
      "nct_id": "NCT02854605",
      "title": "Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "GS-9674",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match GS-9674",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 140,
      "start_date": "2016-10-26",
      "completion_date": "2018-01-09",
      "has_results": true,
      "last_update_posted_date": "2019-01-29",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02854605"
    },
    {
      "nct_id": "NCT04197479",
      "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Resmetirom",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1343,
      "start_date": "2019-12-16",
      "completion_date": "2023-01-06",
      "has_results": false,
      "last_update_posted_date": "2023-09-05",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 76,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197479"
    },
    {
      "nct_id": "NCT07270601",
      "title": "Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease",
        "NAFLD - Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Verasonics NXT Data Acquisition System",
          "type": "DEVICE"
        },
        {
          "name": "Philips EPIQ Elite",
          "type": "DEVICE"
        },
        {
          "name": "EchoSense FibroScan",
          "type": "DEVICE"
        },
        {
          "name": "Philips 3T Ingenia Elition",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ContextVision AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 110,
      "start_date": "2025-11-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07270601"
    },
    {
      "nct_id": "NCT02279524",
      "title": "A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fatty Liver",
        "Non-Alcoholic Steatohepatitis",
        "Liver Diseases",
        "Liver Fibroses"
      ],
      "interventions": [
        {
          "name": "Aramchol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galmed Research and Development, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 247,
      "start_date": "2015-04-29",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 17,
      "location_summary": "Chula Vista, California • Los Angeles, California • Pasadena, California + 12 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02279524"
    },
    {
      "nct_id": "NCT03053050",
      "title": "Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match SEL 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match SEL 18 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 808,
      "start_date": "2017-02-13",
      "completion_date": "2019-06-19",
      "has_results": true,
      "last_update_posted_date": "2020-06-29",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 124,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03053050"
    },
    {
      "nct_id": "NCT06419374",
      "title": "A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Pegozafermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "89bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 762,
      "start_date": "2024-05-24",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-09T08:10:11.795Z",
      "location_count": 150,
      "location_summary": "Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06419374"
    }
  ]
}